

Clot-Busting Drug THR-100 (Staphylokinase) Enters Phase III Clinical Trials in India

*Thrombolytic Agent for Treatment of Myocardial Infarction
Being Developed for Emerging Markets by Bharat Biotech*

Hyderabad, India - 04 February 2011 -Bharat Biotech (www.bharatbiotech.com) today announced it has initiated a Phase III trial in India with THR-100 in patients suffering an acute myocardial infarction (AMI or heart attack). Bharat Biotech is a leading innovator and manufacturer of vaccines and biologics with focus on emerging markets. The trial is expected to recruit approximately 120 patients.

Bharat Biotech entered into a license agreement with ThromboGenics for the manufacture, clinical development and commercialization of THR-100 with the objective of potentially commercializing THR-100 as a replacement for established thrombolytics, such as streptokinase and urokinase, in developing markets in December 2006. THR-100, a novel variant of Recombinant Staphylokinase, is a thrombolytic agent developed by ThromboGenics for the treatment of AMI and other vascular diseases, based on its ability to dissolve blood clots.

Bharat Biotech anticipates that the Phase III trial with THR-100 will be completed in the second half of 2011. The results of this Phase III trial will pave the way for this novel thrombolytic to be filed for marketing approval by Bharat Biotech with Indian regulatory authorities.

Media Contact for Bharat Biotech

Sheela Panicker
enRight PR
+91 98498 09594
enright@enrightpr.com



About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product ocriplasmin (microplasmin) has completed two Phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (sVMA). Ocriplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (anti-Factor VIII), a long acting anti-coagulant in Phase II, and TB-403 (anti-PlGF) in Phase Ib/II for cancer in partnership with Roche.

ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on NYSE Euronext Brussels under the symbol THR. More information is available at www.thrombogenics.com.

About Bharat Biotech

Bharat Biotech International Limited, Hyderabad, India, is a multidimensional biotechnology company specializing in innovation for emerging markets, manufacture of vaccines and biotherapeutics. Bharat Biotech, established in 1996, is engaged in developing next-generation vaccines and biotherapeutics through innovative and collaborative research.

Bharat Biotech is one of the first bio-pharma facilities in India to be audited and approved by Korean Food & Drugs Administration (KFDA). Bharat Biotech is also a WHO prequalified manufacturer of Hepatitis-B vaccines for supply to UNICEF and global procurement agencies. Bharat Biotech is one of the largest manufacturer of anti-rabies vaccines in India. INDIRAB® is a market leader in India and several countries globally. Bharat Biotech also manufactures vaccines for typhoid, polio, and pentavalent combination vaccines. Bharat Biotech is a market leader in wound healing segment with its REGEN-D, epidermal growth factor for diabetic foot ulcers, burns and wound healing. www.bharatbiotech.com

Cautionary note regarding forward-looking statements

This press release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of ThromboGenics, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this press release. ThromboGenics expressly disclaims any obligation to update any such forward-looking statements in this press release, unless required by law or regulation. www.thrombogenics.com.